Stockscreener 앱 받기
226.93
0.02%
0.05
시간 외 거래:
226.93
전일 마감가:
$226.88
열려 있는:
$229.41
하루 거래량:
679.88K
Relative Volume:
0.74
시가총액:
$14.26B
수익:
$4.44B
순이익/손실:
$29.49M
주가수익비율:
-12,333.15
EPS:
-0.0184
순현금흐름:
$1.19B
1주 성능:
-1.18%
1개월 성능:
-0.80%
6개월 성능:
+37.60%
1년 성능:
+111.99%
1일 변동 폭
$224.61
$229.41
1주일 범위
$224.61
$236.71
52주 변동 폭
$105.00
$243.32
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
명칭
Jazz Pharmaceuticals Plc
전화
353-1-634-7800
주소
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
226.93 | 14.49B | 4.44B | 29.49M | 1.19B | -0.0184 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 재개 | Raymond James | Outperform |
| 2026-02-27 | 개시 | Barclays | Overweight |
| 2025-11-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-15 | 개시 | Deutsche Bank | Buy |
| 2025-03-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-26 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Buy |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-11-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-09-29 | 개시 | Raymond James | Mkt Perform |
| 2023-06-12 | 재개 | Wells Fargo | Equal Weight |
| 2022-12-09 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Buy |
| 2022-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-11-19 | 재개 | Goldman | Buy |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-10-05 | 개시 | Citigroup | Buy |
| 2021-09-23 | 개시 | Needham | Buy |
| 2021-05-19 | 재개 | JP Morgan | Overweight |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | 개시 | Jefferies | Buy |
| 2020-03-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Neutral |
| 2019-08-21 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Peer Perform |
| 2018-11-08 | 재확인 | B. Riley FBR | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | 재확인 | H.C. Wainwright | Neutral |
| 2018-03-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Jazz Pharmaceuticals Plc 주식(JAZZ)의 최신 뉴스
[144] Jazz Pharmaceuticals plc SEC Filing - Stock Titan
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN
How Investors Are Reacting To Jazz (JAZZ) Zepzelca Failing Phase 3 LAGOON Survival Endpoint - simplywall.st
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study - Yahoo Finance
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with Strong Buy Ratings and 11% Potential Upside - DirectorsTalk Interviews
Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN
Jazz, AstraZeneca, Astellas: Foreign healthcare's strongest quant picks - MSN
Insider Sell: Neena Patil Sells Shares of Jazz Pharmaceuticals P - GuruFocus
Jazz Pharmaceuticals (JAZZ) Shares Decline After Zepzelca Trial Results - GuruFocus
[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity - Stock Titan
Jazz Pharmaceuticals lung cancer drug fails late-stage trial By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ) Reports Phase 3 Trial Results for Ze - GuruFocus
Jazz Pharmaceuticals' Zepzelca misses primary goal in Phase 3 LAGOON trial - grafa.com
Jazz Pharmaceuticals lung cancer drug fails main trial goal - Reuters
Jazz Pharmaceuticals stock falls after lung cancer trial fails By Investing.com - Investing.com Australia
Jazz Pharmaceuticals stock falls after lung cancer trial fails - Investing.com
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial By Investing.com - Investing.com Australia
Jazz Pharmaceuticals’ Zepzelca fails phase 3 lung cancer trial - Investing.com
Jazz Pharma's lung cancer drug fails late-stage trial - marketscreener.com
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer - PR Newswire
MIdWestOne Financial Group Inc. Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
UBS upgrades Jazz Pharmaceuticals (JAZZ) - MSN
New Xywav Data And FDA Ruling Put Jazz Valuation In Focus - Yahoo Finance
Daiwa Securities Group Inc. Has $1.46 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Allianz Asset Management GmbH Boosts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst - Benzinga
JAZZ Maintained by B of A Securities -- Price Target Raised to $307 - GuruFocus
Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $259.28, Implies 13% Upside - TradingView
GW&K Investment Management LLC Sells 27,068 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
BofA raises Jazz Pharmaceuticals stock price target on Ziihera sales By Investing.com - Investing.com UK
Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Franklin Resources Inc. - MarketBeat
Bernstein SocGen reiterates Jazz Pharmaceuticals stock rating at Market Perform - Investing.com UK
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential - ChartMill
Truist assumes Jazz Pharmaceuticals stock with buy on oncology growth By Investing.com - Investing.com UK
Jazz Pharmaceuticals plc ($JAZZ) President, CEO and Director 2025 Pay Revealed - Quiver Quantitative
Jazz Pharmaceuticals (JAZZ) sets 2026 AGM on directors, pay and share issuance powers - Stock Titan
These healthcare stocks have maintained strong buy ratings for months - MSN
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Los Angeles Capital Management LLC - MarketBeat
Jazz Pharmaceuticals plc (JAZZ) Stock Analysis: Navigating a 6.14% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Capital World Investors Has $453.32 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
CenterBook Partners LP Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Xywav And Ziihera Updates And Strong Quarterly Results - simplywall.st
ETFs Investing in Jazz Pharmaceuticals Public Limited Company Stocks - TradingView
Jazz Pharmaceuticals Public Limited Company Trade Ideas — XETR:J7Z - TradingView
Bank of New York Mellon Corp Purchases 715,361 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (NASDAQ: JAZZ) CEO donates 600 shares - Stock Titan
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - marketscreener.com
Jazz Pharmaceuticals (NASDAQ:JAZZ) Flashes Perfect Minervini Trend Template Score with 116% Annual Surge - ChartMill
Globeflex Capital L P Takes $780,000 Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals Plc (JAZZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Jazz Pharmaceuticals Plc 주식 (JAZZ) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patil Neena M | EVP & Chief Legal Officer |
Jun 10 '26 |
Sale |
231.83 |
1,200 |
278,196 |
51,549 |
2.60%
0.94%
자본화:
|
볼륨(24시간):